TrovaGene, Inc., Achieves Intellectual Property Milestone Under License Agreement with Ipsogen
8/29/2012 10:00:34 AM
More...
|
QIAGEN N.V. (QGEN) Reaches Agreement To Buy 61% Stake In Ipsogen, Plans To Fully Acquire Leader In Oncology Molecular Diagnostics
7/11/2011 6:19:21 AM
More...
|
QIAGEN Inc. (QGEN) Plans to Buy Cancer MDx Firm Ipsogen for $101 Million
6/15/2011 9:30:06 AM
More...
|
The Institut Curie and Ipsogen Sign a Scientific Collaboration Agreement Relating to the Genomic Grade, a Molecular Diagnostic Tool for Breast Cancer
1/11/2010 8:44:30 AM
More...
|
Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting
7/10/2009 8:39:12 AM
More...
|
Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays
5/4/2009 7:08:56 AM
More...
|
Ipsogen Announces the CE Marking of its "ProfileQuant(R) WT1" Kit
3/16/2009 7:43:56 AM
More...
|
Ipsogen Reinforces its Leadership in Molecular Diagnosis and Monitoring of Leukemia
1/12/2009 10:45:04 AM
More...
|
Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer
11/24/2008 8:33:39 AM
More...
|
Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer
11/24/2008 6:39:59 AM
More...
|
|